Authors
Latest:
Introducing Humanities Into the Oncology CurriculumIt seems that every year, the list of Accreditation Council for Graduate Medical Education (ACGME) requirements grows longer and more bewildering.
Latest:
Dr. Nanus Discusses Early Stage Kidney Cancer TreatmentDavid M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment for patients with early-stage kidney cancer.
Latest:
Dr O'Malley on Updates in Gynecologic Oncology at the 2024 ASCO Annual MeetingDavid M. O’Malley, MD, and Chandler H. Park, MD, FACP, discuss updates in gynecologic oncology at the 2024 ASCO Annual Meeting.
Latest:
Dr. Carbone on the Impact of Immunotherapy in Lung CancerDavid P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.
Latest:
Dr. Mason on Progress Made in Resectable Stage III Lung CancerDavid P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Health, chief of lung transplantation, head of the Department of Thoracic Surgery, Baylor University Medical Center, discusses the progress that has been made in resectable stage III lung cancer.
Latest:
Dr. Steensma on the Utility of Venetoclax in MDSDavid P. Steensma, MD, discusses the potential utility of venetoclax in myelodysplastic syndrome.
Latest:
CMS Decision Helps Unlock the Potential of Next-Generation TestingProvisions to a final national coverage determination that expanded coverage for next-generation sequencing tests have implications for any NGS-based cancer test provided to Medicare beneficiaries and will inevitably influence the coverage thinking of commercial payers.
Latest:
Dr. Pearlstone Discusses Mammogram DeterrentsDr. David Pearlstone from John Theurer Cancer Center Discusses Mammogram Deterrents
Latest:
Dr. Piccioni on Tumor Profiles of Brain MetastasesDavid Piccioni, MD, PhD, assistant professor, Neuroscience and Neuro-Oncology, UC San Diego Health, discusses tumor profiling of brain metastases of patients with non-small cell lung cancer, breast cancer, and melanoma.
Latest:
Dr. Planchard on Dabrafenib/Trametinib Combo in Advanced NSCLCDavid Planchard, MD, PhD, Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, discusses a phase II trial examining the combination of dabrafenib and trametinib in pretreated patients with BRAF V600E-mutant advanced non–small cell lung cancer (NSCLC).
Latest:
Dr. Polsky on the Association Between ctDNA and Survival in MelanomaDavid Polsky, MD, PhD, on the association between circulating tumor DNA and survival in melanoma.
Latest:
Dr. Gandara on Incorporating MRD Testing into Lung Cancer PracticeDavid R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.
Latest:
Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MDDr Gandara discusses the optimal use of liquid biopsy for patients with NSCLC and available treatment options for patients with KRAS-mutant NSCLC.
Latest:
Dr Spigel on the Efficacy of Durvalumab Consolidation Therapy in LS-SCLCDavid R. Spigel, MD, discusses findings from the phase 3 ADRIATIC trial in patients with limited-stage small cell lung cancer.
Latest:
Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC TrialDavid R. Spigel, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the updated results from the phase 3 PACIFIC trial of durvalumab treatment after chemotherapy in patients with unresectable stage III non-small cell lung cancer
Latest:
Dr Wise on the Impact of Genetic Testing on Patient Outcomes in Prostate CancerDavid R. Wise, MD, PhD, discusses progress made in the treatment of patients with metastatic castration-resistant prostate cancer.
Latest:
Rapid Readouts: Results of the SCOUT and NAVIGATE TrialsDavid A. Reardon, MD, presents slides, shown at the 2021 American Society of Clinical Oncology Annual Meeting, from the phase 2 NAVIGATE basket trial and the phase 1/2 SCOUT trial in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion–positive primary central nervous system (CNS) tumors treated with larotrectinib with or without prior therapy.
Latest:
Dr Rimm on the Effect of Inaccurate HER2 IHC Testing for Patients With Breast CancerDavid Rimm, MD, PhD, discusses the effect of inaccurate HER2 immunohistochemistry testing on the subclassification of patients with breast cancer.
Latest:
Dr. Ritchie on Immunological Recovery With Venetoclax and Ibrutinib in MCLDavid Ritchie, MD, PhD, discusses immunological recovery with venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma.
Latest:
Dr. Camidge on Biomarker Combinations in NSCLCDavid Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses biomarker combinations in non–small cell lung cancer (NSCLC).
Latest:
Dr Hong on Preliminary Activity With RMC-6291 in Advanced KRAS G12C–Mutant Solid TumorsDavid S. Hong, MD, discusses preliminary efficacy data from a phase 1 trial f the KRAS G12C inhibitor RMC-6291 in advanced KRAS G12C–mutant solid tumors.
Latest:
Dr Siegel on the Need for Durable Remissions in Patients With Multiple MyelomaDavid Samuel Dicapua Siegel, MD, discusses unmet needs and current challenges within multiple myeloma.
Latest:
Dr. Snyder on How Ruxolitinib and Fedratinib May Pave the Way to Transplant in MyelofibrosisDavid S. Snyder, MD, discusses how ruxolitinib and fedratinib may be used to pave the way toward transplant for patients with myelofibrosis.
